Welcome to the BioLogicTube

Dr. Jesper Eugen-Olsen talks on suPAR and Chronic inflammation

Tue, 16 Jul 2024 10:41:27 GMT

Dr Eugen-Olsen talks on chronic inflammation and how it is linked to the development of disease. The lecture is from the Longevity and Biohacking Conference in Andorra, July 2024 and is named "Cracking the longevity code: Measuring and mastering chronic inflammation"

Routine use of suPARnostic in the Emergency Department

Wed, 15 Nov 2017 14:48:58 GMT

At Copenhagen University Hospital Hvidovre, suPAR is measured as part of the routine biomarkers. suPAR is used as support for the decision to admit or discharge the acute medical patient. For more info on the suPARnostic products, please go to Virogates.com

suPAR - From basic research to routine clinical use - Danish speak

Sun, 10 Apr 2016 20:54:55 GMT

suPAR is today a routine marker used for accessing disease severity and prognosis in the Emergency Department. The movie is produced by Copenhagen University Hodpital Hvidovre. Photo and edit Peter Bak

Jesper Eugen-Olsen fortæller om suPAR

Tue, 04 Aug 2015 14:09:19 GMT

Klippet indgik i "Live fra tarmen" produceret af DR/ Lars Ostenfeld

Hvidovre Hospital - why we have implemented suPAR in clinical routine

Thu, 09 Jul 2015 14:24:23 GMT

In this movie, the Vice President, MD, Dm.Sc Torben Mogensen and the Hospital Research Director, MD, PhD Ove Andersen explains why suPAR has been implemented in routine use in the Emergency Department.

suPARnostic Quick Triage Test Instruction Video

Wed, 17 Jun 2015 09:02:43 GMT

Instruction video for the quantitation of suPAR in plasma using the Quick Triage test. The test is based on the lateral flow principle and quantifies the patient plasma suPAR value (The new updated quantitative Quick triage test). The time from plasma sample to final result is about 24 minutes. The suPARnostic Quick Triage Test is produced by ViroGates, Denmark. More information on suPAR measuring products can be found at www.suPARnostic.com

Overview of the 5'th International suPAR symposium

Fri, 25 Jul 2014 14:38:49 GMT

The 5th suPAR symposium was hosted by Prof. Markus Schultz and held at the Amsterdam Medical Center in May 2014. New and recently published data were presented and gave insights into the clinical use of suPAR. This years focus was on the use of suPAR as a risk triage marker in the Acute Medical Department. Data from the routine use as well research data complemented into a conclusion that suPAR helps changing the clinical decision. Should the patient be admitted? Sent home? Rushed to the ICU? This and more was discussed by almost 100 clinicians and researchers over the 2-day seminar.

Dr. August Wrotek talks on suPAR as marker of severity of pneumonia in children

Fri, 13 Jun 2014 11:43:12 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Wrotek's presentation was one of 25 lectures given over the 2-day 5'th International suPAR symposium. The programme and info on the conference can be found here: www.ViroGates.com

Dr. Martin Höenigl talks on suPAR and risk stratification in the Acute care...

Fri, 13 Jun 2014 10:47:56 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Höenigll's presentation was one of 25 lectures given over the 2-day Internationl suPAR symposium and The groups work was published in Journal of Internal Medicine in 2014 (http://www.ncbi.nlm.nih.gov/pubmed/24645798) and was accompaigned by an editorial (http://www.ncbi.nlm.nih.gov/pubmed/24734882).

Lifandis - Unlocking the secrets of disease

Wed, 09 Apr 2014 14:29:18 GMT

Lifandis links the industry to a wealth of biological samples from the HUNT studies. It is the entry point to a unique set of biological samples and extensive clinical and longitudinal data based on the Norwegian population. By connecting industry to high quality biosamples, a comprehensive network of national health registries, and depth information about health and disease we offer unparalleled access to this population.

Lifandis advances disease understanding and leads to better healthcare products.

Lifandis is owned by the Norwegian University of Science and Technology, the Central Norway Health Authority and the Nord-Trøndelag County.

The company changed its name from Hunt Biosciences AS to Lifandis AS as of April 1, 2014.

For more info, please check www.lifandis.com

5'th International suPAR symposium, Amsterdam May 8-9th, 2014

Sat, 29 Mar 2014 11:18:41 GMT

The 5th International suPAR symposium is hosted by Professor Marcus Schultz from The Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam.
This years theme is "suPAR and its value in clinical use". Information on Programme, registration and accommodation can be found here: http://suparnostic.com/index.php/events/supar-symposias/5th-international-supar-symposium

4th International suPAR symposium Overview

Wed, 20 Nov 2013 16:13:27 GMT

Almost 100 researchers met to present new data and discuss the potential of the suPAR biomarker in triage in the emergency room and ICU setting.

The 4th International suPAR symposium was held in late February in 2013 in Aachen, Germany.

This years suPAR symposium was entitled ” New Horizons for suPAR: Risk Stratification, Organ Dysfunction and Relevance for Specific Diseases”.

Almost 100 researchers from all over the world met to discuss the potential use of the prognostic biomarker suPAR.

The symposium was hosted by Professor Frank Tacke and Dr Alexander Koch from Aachen University Hospital

The talks started with insights into suPAR biology and pathology with ”state of the art lecture” given by professor Jochen Reiser from Chicago on the causative effect of suPAR in kidney diseases. This was followed by an overview on suPAR in Kidney diseases, liver diseases and finally in pulmonary diseases.

The overviews were followed by presentations on exciting new data on suPAR in liver cirrhosis – where does suPAR come from, how is it regulated, what is its prognostic relevance?

Hereafter chief Physician Jyrki Tenhunen gave an overview on the large amount of data published within the last year with emphesis on sepsis

Finally, on day 1, new data on suPAR and its prognostic value in Inflammatory and Infectious Diseases and Sepsis were presented and the Usefulness of suPAR in Risk Stratification of Patients with sepsis Admitted to the Emergency Department were discussed

As the day turned into night, the researchers met to socialize and exchange ideas at the suPARTY.

On day 2, after some black coffee, the researchers presented data and discussed how biomarkers may aid in clinical decision making – in particular in sepsis, Cardiology, Kidney failure, liver failure and finally in cancer.The last session gave insight into the use of suPAR as a marker of triaging in the emergency department. And Katia Donadello closed the symposium with a presentation on the potential use of suPAR in the intensive care unit.

The 4'th International suPAR symposium overview

Tue, 21 May 2013 18:55:50 GMT

Almost 100 researchers met to present new data and discuss the potential of the suPAR biomarker in triage in the emergency room and ICU setting.

The 4th International suPAR symposium was held in late February in 2013 in Aachen, Germany.

This years suPAR symposium was entitled ” New Horizons for suPAR: Risk Stratification, Organ Dysfunction and Relevance for Specific Diseases”.

Almost 100 researchers from all over the world met to discuss the potential use of the prognostic biomarker suPAR.

The symposium was hosted by Professor Frank Tacke and Dr Alexander Koch from Aachen University Hospital

The talks started with insights into suPAR biology and pathology with ”state of the art lecture” given by professor Jochen Reiser from Chicago on the causative effect of suPAR in kidney diseases. This was followed by an overview on suPAR in Kidney diseases, liver diseases and finally in pulmonary diseases.

The overviews were followed by presentations on exciting new data on suPAR in liver cirrhosis – where does suPAR come from, how is it regulated, what is its prognostic relevance?

Following this, new data on the role of suPAR in low-grade inflammation, Atherosclerosis and Life Style Diseases were presented and discussed and approximately half of the attendees had their blood drawn for suPAR measurement

Hereafter chief Physician Jyrki Tenhunen gave an overview on the large amount of data published within the last year with emphesis on sepsis

As the day turned into night, the researchers met to socialize and exchange ideas at the suPARTY.

From 1st to 4th suPAR symposium - What have we learned?

Tue, 21 May 2013 15:46:02 GMT

suPAR researcher Jesper Eugen-Olsen gives an overview of the suPAR data generated during the symposiums.

suPAR and APACHE II score in risk assesment in critically ill patients by Dr...

Tue, 14 Aug 2012 11:58:51 GMT

Dr Evangelos Giamarellos-Bourboulis talks on the combined use of suPAR and APACHE II score in risk assesment in critically ill patients. The work by Giamarellos-Bourboulis and coworkes was published August 8th, 2012 in Critical Care and entitled "Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor" and can be read here http://ccforum.com/content/16/4/R149/abstract

Teaser for the 4th International suPAR symposium, 2013

Wed, 18 Jul 2012 21:20:17 GMT

The 4th International suPAR symposium will be hosted by Drs. Frank Tacke and Alexander Koch from Aachen University Hospital in Germany. The symposium will be held at the super C building in Aachen on the 25-26th of February 2013.

suPAR as a prognostic biomarker in the acute care setting

Tue, 05 Jun 2012 21:01:45 GMT

A simple suPAR measurement has similar or better predictive value of mortality than SOFA score (sequential organ failure assessment score), a sepsis mortality risk algorithm including multiple laboratory and clinical measures. This and other aspects of the use of suPAR in an acute care setting was discussed at the 2nd International suPAR symposium in Copenhagen, Denmark 2011

The crystal ball biomarker - is your life killing you?

Tue, 05 Jun 2012 20:55:49 GMT

The suPAR molecule and its predictive value and role as a life style and risk biomarker is discussed at the second international suPAR symposium in Copenhagen 2011

suPAR - the inflammatory biomarker that provides unique prognostic evidence

Tue, 11 Oct 2011 11:13:18 GMT

A short movie on suPAR

To read more on suPAR, click here:
http://chronopause.com/index.php/2011/07/14/supar-power-a-rapid-inexpensive-highly-accurate-method-of-predicting-all-cause-and-disease-specific-mortality/

Or search www.pubmed.com using keyword suPAR

17-02-2020

Tue, 11 Oct 2011 09:13:18 GMT

A short movie on suPAR

To read more on suPAR, click here:

http://chronopause.com/index.php/2011/07/14/supar-power-a-rapid-inexpensive-highly-accurate-method-of-predicting-all-cause-and-disease-specific-mortality/

Or search www.pubmed.com using keyword suPAR

suPAR and HIV infection by Dr Ostrowski - Part 2

Fri, 30 Sep 2011 14:03:01 GMT

MD, PhD, DmSc Sisse Ostrowski gives insight into the inflammatory biomarker suPAR in HIV pathogenesis. Dr Ostrowski has published several papers in the field and gives and overview of the published data at the 2nd suPAR symposium in Copenhagen in 2011

Case stories for the ICU - suPAR and prognosis by Prof Paradowski

Fri, 30 Sep 2011 13:41:35 GMT

Professor Marek T Paradowski from Veterans Central University Hospital in Lodz, Poland, studies the kinetics and prognostic ability of the biomarkers Procalcitonin (PCT), C-reactive Protein (CRP) and soluble urokinase receptor (suPAR). The talk was given at the 2nd suPAR symposium in Copenhagen 2011.

suPAR and HIV infection by Dr Ostrowski - Part 1

Fri, 30 Sep 2011 13:36:27 GMT